Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?

Janneke Anink*, Marieke H. Otten, Simone L. Gorter, Femke H. M. Prince, Marion A. J. van Rossum, J. Merlijn van den Berg, Philomine A. van Pelt, Sylvia Kamphuis, Danielle M. C. Brinkman, Wijnand A. A. Swen, Joost F. Swart, Nico M. Wulffraat, Koert M. Dolman, Yvonne Koopman-Keemink, Esther P. A. H. Hoppenreijs, Wineke Armbrust, Rebecca ten Cate, Lisette W. A. van Suijlekom-Smit

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1674-1679
JournalRheumatology
Volume52
Issue number9
DOIs
Publication statusPublished - Sep 2013

Keywords

  • juvenile idiopathic arthritis
  • TNF-alpha inhibitors
  • qualitative research
  • decision making

Cite this